



# Updates in Diagnosis and Management of Melasma : A Simple Review Article

Dhaifallah Alenizi <sup>a\*</sup> and Shahad Fahis A. Alanazi <sup>a</sup>

<sup>a</sup> Northern Border University, Saudi Arabia.

## Authors' contributions

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

## Article Information

DOI: 10.9734/AJMAH/2022/v20i230442

## Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/83666>

Review Article

Received 20 December 2021  
Accepted 25 February 2022  
Published 28 February 2022

## ABSTRACT

Melasma is a long-term skin condition characterized by bilateral, hyper pigmented, irregularly shaped macules on the cheeks, forehead, and jaw. It's a broad-minded, macular, nonscaling hypermelanosis of sun-exposed skin that mostly affects the face and forearms. It's usually linked to pregnancy or the use of oral contraceptives or anticonvulsants (such as phenytoin [Dilantin]), but it can also be idiopathic. Melasma can be identified based on the patient's normal clinical symptoms. Some patients may object to the use of products with strong smells or an oily foundation, as well as the use of camouflaging proxies. Furthermore, some patients may find applying skin care products multiple times a day or smoothing once a day unattractive, and physicians should be aware of this.

**Keywords:** Melasma; skin; hyperpigmentation; updates; management.

## 1. INTRODUCTION

Melasma and post-inflammatory hyperpigmentation (PIH) are pigmentary illnesses in which melanin production is increased in response to a range of stimuli. The hyperpigmentation that develops can have a substantial influence on the quality of life of these people, especially when exposed parts like the

face are implicated [1]. Between 1994 and 2010, over 24.7 million dermatological consultations for dyschromia management were made, making pigmentation disorders the 11th most common condition encountered by dermatologists [1,2].

Photoprotection was the tenth most common treatment decision administered to Asians and the sixth most common for African Americans in

\*Corresponding author: E-mail: elshmaa3332004@yahoo.com;

the National Ambulatory Medical Care Survey, compared to the third most common in Caucasians for the treatment of dyschromia, according to Kang et al research. [1]. This contradiction draws attention to these changes. The higher melanin content and more responsive melanosomes in melanocompetent people predispose them to hyperpigmentation, which is often more visible and lasts longer than in lighter-skinned people [3,4]. The incidences of melasma in different areas around the world was 1.8% in Ethiopia, 3.4% in Beirut, 8.8% in Dallas, TX, USA, and 10.1% in Peru [5].

Melasma is a reforming, macular, skin hypermelanosis. The face and dorsal forearms are the areas most affected. It is most commonly appears with pregnancy or the administration of oral contraceptives or anticonvulsants, but it can occur idiopathic. Melasma unreasonably disturbs womankind (9:1), in addition to skin types IV to VI [6]. It is normally have no symptoms; nonetheless the patient could find it ugly. The three most common distribution schemes are centrofacial (63%), malar (21%), and mandibular (21%). (16%)[6]. Melasma is frequently, but not always, bilateral. Under the Wood Lamp, the melasma turns light brown and improves. The colour of dermal melasma is grey, and it has no boosting characteristics. Melasma is a dark brown melasma with variable augmentation in mixed types. Topical therapy does not work for dermal melasma [6].

Melasma is tough to cure because it relapses on its own. Melasma aetiology, clinical staging and categorization, and clinical administration have all improved significantly in recent year [7,8].

There have been new investigations that have shed light on other components that may be involved in the pathophysiology of melasma. These include H19, inducible nitric oxide synthase (iNOS), and Wnt pathway modulator genes, as well as genetic aspects and the involvement of H19, iNOS, and Wnt pathway modulator genes. Identifying these elements could be beneficial [9].

### 1.1 Epidemiology

Melasma's prevalence rate in the overall populace, both genders, is unknown. This possibly be owing to exaggerated patients' under-recording, as well as the fact that a lot of patients prefer to manage their acne with self-medication instead of visiting a dermatologist

[10]. Melasma occurrence varies with civilization, skin kind, and level of sun revelation around the world. It was discovered that Hispanics, Asians, and African Americans are more mutual than Caucasians. It's also more common among dark-skinned persons and Fitzpatrick skin categories IV, V, and VI [11,12].

Melasma affects 1.8 % of Ethiopians [13], 2.8% in Saudi Arabia [14], 3.4% in Lebanon [15], then 8.2% in the USA [16]. Melasma is more common in South Asian countries such as Nepal (6.8%) and China than in other countries (13.6% ) [17,18].

Melasma affects about 1% of the general population, but it can affect anywhere from 9% to 50% of those living in high-risk areas. In Central and South America, melisma affects between 4% and 10% of people who visit dermatology clinics. Melasma is more common in women who are pregnant or planning to become pregnant. The average age of onset was roughly 28 years in two Brazilian investigations. The average age of onset in 140 cases from India was 37 years [6]. The average age of onset was 34 years in a survey of 324 women living with melasma in nine countries. The Fitzpatrick phototype of a patient may have an impact on the onset stage. The average age of onset for type II melasma patients in a cohort of Brazilian patients was 27 years.

### 1.2 Etiology

Melasma has three key pathogenic aspects: genetic predisposition, solar exposure, and sex hormone levels changes. The pathophysiology of melasma is also complicated by excessive melanin synthesis, angiogenesis, [19] skin barrier failure, and inflammation at the lesional site.

### 1.3 Predisposition Due to Genetics

Individuals with Fitzpatrick skin types III to V in darker-skinned races expected to have melisma more than others. Patients with a family history of melasma are more likely to have a negative reaction to treatment [20,21].

### 1.4 Exposure to Sunlight

Long-wave ultraviolet light stimulate melanocytes to produce melanin. UV light causing melanin to diffuse into the dermis, elastic fibre degeneration, and skin photoaging. It can also arouse fibroblasts, mast cells, and sebaceous gland

cells to secrete melanogenesis factors which can activate tyrosinase and improve melanocyte function, resulting in increased melanin synthesis [22,23,24].

### 1.5 Sex Hormones

Gravidity, hormonal contraceptives, and HRT (hormone replacement therapy) can cause and exaggerate melasma [20,21,25].

### 1.6 Exaggerated Melanin Synthesis

Various stimuli up-regulate and stimulate melanocytes and enhance melanin synthesis.

### 1.7 Vascular Issues

Melasma lesions have a significantly increased the vascularity than normal skin [19].

### 1.8 Inflammation

The prostaglandin E2 and stem cell factor is augmented, increases the melanogenesis. Intensifications in inflammatory proteins can also trigger melanogenesis [26,27].

### 1.9 Skin Barricade Dysfunction

The anomalous appearance of keratin, in melasma lesions can result in epidermal permeability barricade dysfunction, which can lead to an increase in ultraviolet light-induced melanin production. [28,29].

Melasma can be caused or aggravated by sleep issues, the use of cosmetics containing high mercury, heat radiation (for example, cooking), and other illnesses such as thyroid disease, female reproductive system disease, and liver disease.

### 1.10 Pathophysiology

The most essential aspect is sunlight exposure. UV radiation stimulates the production of alpha-melanocyte-stimulating hormone and corticotropin, as well as interleukin 1 and endothelin 1, all of which help intraepidermal melanocytes produce more melanin. Dermal inflammation and fibroblast activation caused by prolonged UV exposure upregulate stem cell problems in the melasma dermis, resulting in enhanced melanogenesis [30].

## 2. HISTOPATHOLOGY

Melasma is usually identified through clinical examination. However, a skin biopsy with histological examination (HPE) is possible. Men's melasma histology is comparable to women's [31]. In epidermal melasma, increased melanin is detected in the basal and suprabasal layers, where dendritic melanocytes and melanophages are present, as opposed to the dermal type, which has dendritic melanocytes and melanophages. In an Indian investigation, HPE was conducted on 48.8% (20/41) of male patients, and the results revealed that epidermal melasma was the most common pattern (50%), followed by mixed melasma (25%) (45%). Dermal melasma was the least prevalent kind of melasma (5%). Other topographies included solar elastosis in 17 (85%) male patients with no basal layer signal, flattening of rete ridges in nine (45%) male patients with no basal layer signal, and ongoing inflammatory infiltrate in six (30%) male patients with no basal layer signal. In line with this study, two other studies identified epidermal melasma as the most common histopathological type in men. Jang et al [43] discovered that male patients had more epidermal melasma and enlarged elastotic material in the lesional dermis compared to the nonlesional dermis, but the difference was not statistically significant [30].

### 2.1 Melasma in Males

Melasma is a common skin disorder, which is represented by a symmetrical, uneven light, which is a symmetrical and uneven light connected to a sunscreen area, especially a dark brown hypergly. Although it can affect the people of all races and monolithic, it is more common for women and dark living people who live in a place with a powerful ultraviolet (UV) radiation [32,33]. Irritables in the open part of the body, such as a person, can be a cosmetic alarm for the patient, and the quality of life (QOL) can be reduced. Women's Melasma was considered at the depth, but in the clinical, patient and therapeutics of Melasma, there is a clear difference in clinical, patient and therapeutic features of melasm. Understanding the specific characteristics of melasma in men can improve treatment. Melasma appears as well-defined, symmetrical brown-black hyperpigmented patches on exposed areas of the skin. With a few minor changes, the clinical symptoms of melasma in men are similar to those in women. Melasma can appear at any age in male patients

aged 18 to 72 years, with an average age of onset of 30.7 years [34-36].

### 3. DIAGNOSIS

While melasma is a common differential diagnosis, it can be confused with other skin conditions [37]. A thorough medical history, a thorough clinical examination of the skin, dermoscopy, and histology all contribute to a good diagnosis.

Melasma can also be identified based on the patient's typical clinical symptoms. Melasma can be further theatricalized and typed utilising noninvasive recognition procedures like diascopy and Wood's lamp examination, which can help with melisma classification and documentation [38,39].

#### 3.1 Prognosis

Melasma is not associated with any mortality or morbidity. There have been no reports of malignant transformation or associations with an increased risk of melanoma or other cancers. Melasma patients are thought to be at a lower risk of developing melanoma.

Because there is no effective medication for removing dermal pigment, it may take longer for it to resolve than epidermal pigment. However, treatment should not be withheld just because of a prevalence of dermal pigment. The epidermis is the foundation of dermal pigment, and if epidermal melanogenesis is suppressed for a long time, the dermal pigment will not replenish and will gradually dissolve. Resistant cases or reappearances of melasma occur often and are certain if strict avoidance of sunlight is not severely followed [30].

### 4. MANAGEMENT

Many doctors assume that their male patients are less worried about their skin's look than women are, and that they will be unwilling to adhere to a strict skin care regimen. However, physicians should keep in mind that if a male patient is seeking therapy for a dermatological problem like melasma, cosmesis may be of secondary importance to him, and hence the patient may be highly motivated to follow a prescribed treatment regimen. Clinicians should consider each patient's particular demands when developing treatment regimens in order to inspire the greatest gradation of treatment adherence,

as men and women's tastes and expectations may differ greatly. Use of crops having strong scents, For example, the use of strong flavor cultures or oily bases or the use of masking agents may not be appropriate for some patients. In addition, some patients may negotiate the idea of applying unattractive skin care products several times a day or even once a day, and the clinician will be aware of this before develop their treatment plan. In addition, patient therapy is an integral part of the management of melasma and clinicians should educate their patients about the etiology, prevention and treatment methods, and recurrence rates. broadcast [40].

Avoiding the sun is the most important part of treating melasma, both to improve the present and to prevent future recurrence. The use of broad-spectrum (UVA and UVB) sunscreens as well as inorganic (physical-blocking) sunscreens such as zinc oxide or titanium dioxide with a minimum sun protection level of 15 is recommended [41] Any Regardless of gender, physicians should advise all patients on sun protection, emphasizing regular and optimal application of sunscreen and sun hat and clothing. God. Physicians should exercise extreme caution in male patients, whose exposure is less successful in following sunscreen use guidelines [42].

Melasma can be slow to retort to treatment, particularly if the condition has been present for many years [43]. Poor prognostic issues for melasma treatment include:

Fitzpatrick skin types III–V

Genetic and familial predisposition.

Long-standing disease  $\geq 2$  years persisting despite treatment.

History of procedural interventions (eg lasers).  
History of management by  $\geq 2$  physicians (possibly suggesting long duration and recalcitrant disease.

Long-term self-treatment with topical steroids  
Ochronosis from hydroquinone use – either long term or great strength  
Mixed-type melasma.

### 5. CONCLUSION

Melasma is a complex disorder with many factors at play in its pathogenesis. Understanding these factors will help us develop better treatment

options that are more effective, have fewer side effects, and last longer [44-47]. Newer substances, particularly botanical extracts and device-based managements, are being developed and added to the management alternatives available. However, more randomised controlled trials are needed to assess their efficacy in comparison to currently available treatments.

## CONSENT

It is not applicable.

## ETHICAL APPROVAL

It is not applicable.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Kang SJ, Davis SA, Feldman SR, McMichael AJ, Dyschromia IN. Skin of Color. *J Drugs Dermatol*. 2014;13:401–6. [Pub Med] [Google Scholar]
2. Mohammad TF, Hamzavi IH. Practice and educational gaps in abnormal pigmentation. *Dermatol Clin*. 2016;34:291–301. [PubMed] [Google Scholar]
3. Cayce KA, McMichael AJ, Feldman SR. Hyperpigmentation: An overview of the common afflictions. *Dermatol Nurs*. 2004;16:401. [PubMed] [Google Scholar]
4. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: A comparative practice survey. *Cutis*. 2007;80:387–94. [PubMed] [Google Scholar]
5. Wright CY, Davids LM, Summers B, Norval M. Solar ultraviolet radiation in South Africa: Clinical consequences for the skin. *Expert Rev Dermatol*. 2014;8:693–706. [Google Scholar]
6. Plensdorf S, Martinez J. Common pigmentation disorders. *Am Fam Physician*. 2009;79(2):109–116.
7. Passeron T, Picardo M. Melasma, a photoaging disorder. *Pigment Cell Melanoma Res* 2018;31:461–465. DOI:10.1111/pcmr.12684.
8. Pigmentary Disorder Group, Committee on Dermatology and Venereology, China Society of Integrated Traditional Chinese and Western Medicine, Research Center for Vitiligo, Chinese Society of Dermatology, Workgroup on Pigmentary Disorders, China Dermatologist Association. Treatment of chloasma in China: an expert consensus statement (2015). *Chin J Dermatol* 2016;49(8): 529–532. DOI:10.3760/cma.j.issn.0412-4030.2016.08.001.
9. Sarkar, R., Arora,P., Garg,V.K., Sonthalia,S., and Gokhale,N.(2014): Melasma updateIndian Dermatol Online J. 2014 Oct-Dec; 5(4): 426–435. DOI: 10.4103/2229-5178.142484
10. Al-Hamdi KI, Hasony HJ, Jareh HL. Melasma in Basrah: A clinical and epidemiological study. *MJBU*. 2008;26:1–5. [Google Scholar]
11. Sarkar R, Puri P, Jain RK, et al. Melasma in men: a clinical, aetiological and histological study. *J Eur Acad Dermatol Venereol*. 2010;24:768–772. [PubMed] [Google Scholar]
12. Pichardo R, Vallejos Q, Feldman SR, et al. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. *Int J Dermatol*. 2009;48:22–26. [PMC free article] [PubMed] [Google Scholar]
13. Hiletework M. Skin diseases seen in Kazanchis health center. *Ethiop Med J*. 1998;36:245–254. [PubMed] [Google Scholar]
14. Parthasaradhi A, Al Gufai AF. The pattern of skin disease in Hail region, Saudi Arabia. *Ann Saudi Med*. 1998;18:558–561. [PubMed] [Google Scholar]
15. Tomb RR, Nassar JS. Profile of skin diseases observed in a department of dermatology (1995-2000) *J Med Liban*. 2000;48:302–309. [PubMed] [Google Scholar]
16. Werlinger KD, Guevara IL, Gonzalez CM, et al. Prevalence of self-diagnosed melasma among pre-menopausal Latino women in Dallas and Forth Worth, Tex. *Arch Dermatol*. 2007;143:424–425. [PubMed] [Google Scholar]
17. Walker SL, Shah M, Hubbard VG, et al. Skin disease is common in rural Nepal: results of a point prevalence study. *Br J Dermatol*. 2008;158:334–338. [PubMed] [Google Scholar]
18. Wang R, Wang T, Cao L et al. Prevalence of melasma in Chinese Han and Chinese

- Yi: a survey in Liangshan district. *Chin J Dermatovenereol.* 2010;24:546–548. [Google Scholar]
19. Kim EH, Kim YC, Lee ES, et al. The vascular characteristics of melasma. *J Dermatol Sci* 2007;46(2):111–116. DOI:10.1016/j.jdermsci.2007.01.009.
  20. Handel AC, Lima PB, Tonolli VM, et al. Risk factors for facial melasma in women: a case-control study. *Br J Dermatol* 2014;171(3):588–594. DOI:10.1111/bjd.13059.
  21. Tamega Ade A, Miot LD, Bonfietti C, et al. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. *J Eur Acad Dermatol Venereol* 2013;27(2):151–156. DOI:10.1111/j.1468-3083.2011.04430.x.
  22. Passeron T, Picardo M. Melasma, a photoaging disorder. *Pigment Cell Melanoma Res* 2018;31:461–465. DOI:10.1111/pcmr.12684.
  23. Hexsel D, Arellano I, Rendon M. Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation. *Br J Dermatol* 2006;156(Suppl 1):7–12. DOI:10.1111/j.1365-2133.2006.07589.x.
  24. Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. *J Invest Dermatol* 2010;130(8):2092–2097. DOI:10.1038/jid.2010.95.
  25. KrupaShankar DS, Somani VK, Kohli M, et al. A cross-sectional, multicentric clinico-epidemiological study of melasma in India. *Dermatol Ther (Heidelb)* 2014;4(1):71–81. DOI:10.1007/s13555-014-0046-1.
  26. Noh TK, Choi SJ, Chung BY, et al. Inflammatory features of melasma lesions in Asian skin. *J Dermatol* 2014;41(9):788–794. DOI:10.1111/1346-8138.12573
  27. Rodríguez-Arámbula A, Torres-Álvarez B, Cortés-García D, et al. CD4, IL-17, and COX-2 are associated with subclinical inflammation in malar melasma. *Am J Dermatopathol* 2015;37(10):761–766. DOI:10.1097/DAD.0000000000000378
  28. Lee DJ, Lee J, Ha J, et al. Defective barrier function in melasma skin. *J Eur Acad Dermatol Venereol* 2012;26(12):1533–1537. DOI:10.1111/j.1468-3083.2011.04337.x...
  29. Li Y, Yang CY, Man MQ, et al. Disruption of epidermal permeability barrier enhances UV-induced hyperpigmentation. *Photodermatol Photoimmunol Photomed* 2020;36(2):156–158. DOI:10.1111/phpp.12515.
  30. Basit H, Godse KV. Al Aboud AM: Melasma Last Update: November 5; 2021.
  31. Rendon MI. Hyperpigmentation Disorders in Hispanic Population in the United States. *J Drugs Dermatol.* 2019;18(3):s112-114. [PubMed]
  32. Pandya AG, Guevara IL. Disorders of hyperpigmentation. *Dermatol Clin.* 2000;18:91–98. [PubMed] [Google Scholar]
  33. Grimes PE. Melasma: etiological and therapeutic considerations. *Arch Dermatol.* 1995;131:1453–1457. [PubMed] [Google Scholar]
  34. Pichardo R, Vallejos Q, Feldman SR, et al. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. *Int J Dermatol.* 2009;48:22–26. [PMC free article] [PubMed] [Google Scholar]
  35. Vazquez M, Maldonado H, Benmaman C, et al. Melasma in men. a clinical and histologic study. *Int J Dermatol.* 1988;27:25–27. [PubMed] [Google Scholar]
  36. Sarkar R, Jain RK, Puri P. Melasma in Indian males. *Dermatol Surg.* 2003;29:204. [PubMed] [Google Scholar]
  37. Pandya AG, Guevara IL. Disorders of hyperpigmentation. *Dermatol Clin.* 2000;18:91–98. [PubMed] [Google Scholar]
  38. Lu Q, Yang C, Wu J, et al. Confocal laser scanning microscopy, a diagnostic alternative for five pigmented lesions on the face: an observational study. *Skin Res Technol* 2019;25(6):871–876. DOI:10.1111/srt.12749.
  39. Huang J, Xu AE. Application of reflectance confocal microscopy and dermoscopy in the efficacy evaluation of comprehensive treatment of melanoses. *Chin J Dermatol* 2018;51(6):440–442. DOI:10.3760/cma.j.issn.0412-4030.2018.06.010.
  40. Sarkar R, Ailawadi P, Garg S: Melasma in Men A Review of Clinical, Etiological, and Management Issues *J Clin Aesthet Dermatol.* 2018;11(2): 53–59. Published online 2018 Feb 1
  41. Krupashankar DS, Godse K, Aurangabadkar S, et al. Evidence-based treatment for melasma: expert opinion and a review. *Dermatol Ther (Heidelb).*

- 2014;4(2):165–186. [PMC free article] [PubMed] [Google Scholar.]
42. Buller DB, Anderson PA, Walkosz BJ, et al. Compliance with sunscreen advice in a survey of adults engaged in outdoor winter recreation at high-elevation ski areas. *J Am Acad Dermatol.* 2012;66:63–70. [PMC free article] [PubMed] [Google Scholar]
43. Oakley A, Doolan BJ, Gupta M. 2020. Melasma. Hamilton, NZ: DermNet NZ, 2020. Available at [dermnetnz.org/topics/melasma](http://dermnetnz.org/topics/melasma) [Accessed 20 August 2021]. Search PubMed
44. Mandry Pagán R, Sánchez JL. Mandibular melasma. *P. R. Health Sci. J.* 2000;19: 231– 234.
45. Sanchez NP, Pathak MA, Sato S. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. *J. Am. Acad. Dermatol.* 1981;4: 698– 709.
46. Taylor SC. Epidemiology of skin diseases in people of color. *Cutis.* 2003;71:271–275. [PubMed] [Google Scholar]
47. Sarkar R, Jagadeesan S, Basavapura Madegowda S, et al. Clinical and epidemiologic features of melasma: a multicentric cross-sectional study from India. *Int J Dermatol* 2019;58(11): 1305–1310. DOI:10.1111/ijd.14541.

© 2022 Alenizi and Alanazi; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*  
*The peer review history for this paper can be accessed here:*  
<https://www.sdiarticle5.com/review-history/83666>